正电子显像剂在乳腺癌诊疗中的应用进展  

Progress in the application of positron imaging agents in the diagnosis and treatment of breast cancer

作　　者：楼伊慧 孙晋[1] 李天女[1] LOU Yihui;SUN Jin;LI Tiannu(Department of Nuclear Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院核医学科,江苏南京210029

出　　处：《南京医科大学学报（自然科学版）》2021年第9期1411-1415,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：江苏省卫生计生委科研项目(Z201502)。

摘　　要：乳腺癌是女性最常见的恶性肿瘤,近年来研究数据表明早期诊断和治疗可显著降低癌症患者的病死率。正电子发射型计算机断层显像/计算机体层成像(positron emission computed tomography,PET/CT)是一种集功能与解剖为一体的无创、全身性的影像检查方法,在乳腺癌临床分期、指导治疗等方面有重要作用。18F-脱氧葡萄糖(18F-fluorodeoxyglucose,18F-FDG)是目前应用最广泛的一种显像剂,因其为非特异性显像剂,在乳腺癌患者中的应用中受到一定限制,所以近年来关于乳腺癌患者特异性受体显像剂的研究日益增多。本文就目前关于乳腺癌PET显像新型分子靶向正电子药物的发展及临床应用进行综述。Breast cancer is the most common malignant tumor among women.In recent years,research data show that early diagnosis and treatment can significantly reduce the mortality of patients with cancer.Positron mission computed tomography(PET/CT)is a noninvasive and systemic imaging method which integrates function and anatomy,and plays an important role in the clinical staging and guiding treatment of brenst cancer.18 F-fluorodeoxyglucose(18 F-FDG)is the most widely used imaging agent.Because of non-specificity,its application in breast cancer patients is limited to some extent.Therefore,for the past few years,there were more researches on the specific receptor imaging agents for breast cancer patients.This paper reviews the development and clinical application of new molecular targeted positron drugs in PET imaging of breast cancer.

关 键 词：乳腺癌 正电子放射性药物 PET/CT 

分 类 号：R737.9[医药卫生—肿瘤]